Prohibitin promotes dedifferentiation and is a potential therapeutic target in neuroblastoma


  • I.C. MacArthur
  • Y. Bei
  • H.D. Garcia
  • M.V. Ortiz
  • J. Toedling
  • F. Klironomos
  • J. Rolff
  • A. Eggert
  • J.H. Schulte
  • A. Kentsis
  • A.G. Henssen


  • JCI Insight


  • JCI Insight 4 (10): e127130


  • Gain of the long arm of chromosome 17 (17q) is a cytogenetic hallmark of high-risk neuroblastoma, yet its contribution to neuroblastoma pathogenesis remains incompletely understood. Combining whole-genome and RNA sequencing of neuroblastomas, we identified the prohibitin (PHB) gene as highly expressed in tumors with 17q gain. High PHB expression correlated with poor prognosis and was associated with loss of gene expression programs promoting neuronal development and differentiation. PHB depletion induced differentiation and apoptosis and slowed cell cycle progression of neuroblastoma cells, at least in part through impaired ERK1/2 activation. Conversely, ectopic expression of PHB was sufficient to increase proliferation of neuroblastoma cells and was associated with suppression of markers associated with neuronal differentiation and favorable neuroblastoma outcome. Thus, PHB is a 17q oncogene in neuroblastoma that promotes tumor cell proliferation and dedifferentiation.